BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ding N, Wei B, Fu X, Wang C, Wu Y. Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis. Front Pharmacol 2020;11:591393. [PMID: 33390969 DOI: 10.3389/fphar.2020.591393] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Gomaa AA, Mohamed HS, Abd-Ellatief RB, Gomaa MA, Hammam DS. Advancing combination treatment with glycyrrhizin and boswellic acids for hospitalized patients with moderate COVID-19 infection: a randomized clinical trial. Inflammopharmacology 2022. [PMID: 35233748 DOI: 10.1007/s10787-022-00939-7] [Reference Citation Analysis]
2 Artlett CM. The Mechanism and Regulation of the NLRP3 Inflammasome during Fibrosis. Biomolecules 2022;12:634. [DOI: 10.3390/biom12050634] [Reference Citation Analysis]
3 Mvubu NE, Chiliza TE. Exploring the Use of Medicinal Plants and Their Bioactive Derivatives as Alveolar NLRP3 Inflammasome Regulators during Mycobacterium tuberculosis Infection. Int J Mol Sci 2021;22:9497. [PMID: 34502407 DOI: 10.3390/ijms22179497] [Reference Citation Analysis]
4 Chen TT, Xiao F, Li N, Shan S, Qi M, Wang ZY, Zhang SN, Wei W, Sun WY. Inflammasome as an Effective Platform for Fibrosis Therapy. J Inflamm Res 2021;14:1575-90. [PMID: 33907438 DOI: 10.2147/JIR.S304180] [Reference Citation Analysis]
5 Hua F, Shi L, Zhou P. Phenols and terpenoids: natural products as inhibitors of NLRP3 inflammasome in cardiovascular diseases. Inflammopharmacology 2022. [PMID: 35039992 DOI: 10.1007/s10787-021-00918-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Oronsky B, Caroen S, Abrouk N, Reid TR. RRx-001 and the “Right stuff”: Protection and treatment in outer space. Life Sciences in Space Research 2022. [DOI: 10.1016/j.lssr.2022.05.001] [Reference Citation Analysis]
7 Özenver N, Efferth T. Phytochemical inhibitors of the NLRP3 inflammasome for the treatment of inflammatory diseases. Pharmacol Res 2021;170:105710. [PMID: 34089866 DOI: 10.1016/j.phrs.2021.105710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]